<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513357</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0901</org_study_id>
    <nct_id>NCT00513357</nct_id>
  </id_info>
  <brief_title>Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients</brief_title>
  <official_title>A Randomized Clinical Trial of Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to evaluate the effectiveness of melatonin for&#xD;
      the management of poor appetite and weight loss in advanced cancer patients. The&#xD;
      effectiveness of melatonin on weight gain, keeping/gaining of lean muscle mass, improved&#xD;
      appetite, and side effects will also be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Melatonin is a hormone that is made by the part of the brain called the pineal gland and may&#xD;
      help in letting your body know when it is time to go to sleep and when it is time to wake up.&#xD;
      The researchers feel melatonin might help to improve your appetite, improve your overall&#xD;
      sense of well-being, and maintain your current weight.&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will see a nutritionist at&#xD;
      the first (baseline) visit. The nutritionist will measure the amount of calories you consume.&#xD;
      You will be asked to report all food and drinks you have had in a 3-day period. If you are&#xD;
      unable to remember what you have eaten and drunk in the last 3 days, you will be asked by the&#xD;
      nutritionist to list all the food and drinks you have had within the last 24 hours.&#xD;
&#xD;
      Your arm muscle diameter and your skin fold below your shoulder blade will be measured on the&#xD;
      arm you don't normally use to write with. This is to determine your body fat, lean mass and&#xD;
      water content of your body.&#xD;
&#xD;
      Your resting energy expenditure will be measured. You will be asked to wear a breathing mask&#xD;
      and to blow into a tube. This will allow your breath to be analyzed, to measure how many&#xD;
      calories your body is using while you are at rest.&#xD;
&#xD;
      Blood (about 1-2 tablespoons) will be drawn for tests to make sure there are no other&#xD;
      treatable causes for your weight loss.&#xD;
&#xD;
      This blood test may not need to be repeated if you have had a blood test in the last 3&#xD;
      months.&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be randomly assigned (as&#xD;
      in the toss of a coin) to one of 2 groups. Participants in Group 1 will take melatonin daily&#xD;
      before bedtime for 4 weeks. Patients in Group 2 will take a placebo daily before bedtime for&#xD;
      4 weeks. A placebo is a substance that looks like the study drug but which has no active&#xD;
      ingredients. You will have an equal chance (50/50) of being placed in either group. Neither&#xD;
      you nor any of the medical staff or researchers on this study will know if you are receiving&#xD;
      the study drug or placebo.&#xD;
&#xD;
      On Week 2, you will return to the clinic and you will repeat all the tests done at the&#xD;
      baseline visit. If you are unable to return to M. D. Anderson to complete the evaluations on&#xD;
      Day 14 (± 2 days), the research nurse will contact you by telephone and ask you about any&#xD;
      side effects you are experiencing.&#xD;
&#xD;
      At Week 4, you will return to the clinic and all the tests done at baseline will be repeated.&#xD;
&#xD;
      At the end of 4 weeks, all study patients in both groups will be given the opportunity to&#xD;
      take melatonin before going to sleep at night for an additional 4 weeks. If you choose not to&#xD;
      continue on melatonin for an additional 4 weeks, you will be taken off study and blood will&#xD;
      be drawn for your end of study tests which include albumin, C-reactive protein (CRP), thyroid&#xD;
      stimulating hormone (TSH), vitamin B-12, and cortisol. These tests will require about 1-2&#xD;
      tablespoons of blood to be drawn. If you choose to continue on melatonin for an additional 4&#xD;
      weeks, you will be asked to return to the outpatient clinic at Week 6 to repeat the tests&#xD;
      done at baseline.&#xD;
&#xD;
      Your end of study tests will be done at the end of 8 weeks.&#xD;
&#xD;
      You will continue to visit the study doctor at the outpatient clinic as long he feels it is&#xD;
      necessary. At these visits, your height and weight will be recorded and you will be asked&#xD;
      what food and drinks you have had.&#xD;
&#xD;
      This is an investigational study. Melatonin is not currently approved by the FDA except to&#xD;
      treat blind people with no light perception for sleep disorders-and is considered a&#xD;
      food/nutritional supplement. Up to 126 patients will be enrolled at MD Anderson and at Duke&#xD;
      University Medical Center in Durham, North Carolina.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Appetite as Measured by ESAS</measure>
    <time_frame>Baseline and at 4 weeks</time_frame>
    <description>Difference in ESAS (Edmonton Symptom Assessment Scale) assessment scores of appetite (symptom) from baseline evaluation [± 3 days] to 4 week evaluation [± 3 days], where the severity at the time of assessment is rated from 0 to 10 on a numerical scale; with 0 meaning that the symptom is absent and 10 that it is the worst possible severity.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Gastrointestinal Cancer</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg of Melatonin before going to sleep at night for a period of 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 mg of Placebo before going to sleep at night for a period of 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>20 mg by mouth daily for 4 Weeks</description>
    <arm_group_label>Melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule by mouth daily for 4 Weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with solid gastrointestinal tumors or lung cancer patients referred to&#xD;
             palliative care and a 5% or more involuntary weight loss within the last 6 months with&#xD;
             anorexia (&gt;3 on visual analog scale such as ESAS)&#xD;
&#xD;
          2. Greater than or equal to 18 years of age&#xD;
&#xD;
          3. Karnofsky score of 40 or higher&#xD;
&#xD;
          4. Patient has the ability to maintain oral food intake during the study period&#xD;
&#xD;
          5. If patients who have persistent anorexia/cachexia and are currently taking Megace,&#xD;
             corticosteroids, non-steroidal anti-inflammatories (NSAID's), or thalidomide, they&#xD;
             should be on the medication at least 2 weeks prior to study inclusion&#xD;
&#xD;
          6. Ability to sign informed consent and understand study procedures&#xD;
&#xD;
          7. Patient can continue all medications including complementary therapies or&#xD;
             antineoplastic therapy while on-study other than melatonin if they have been on stable&#xD;
             dose for at least 2 weeks&#xD;
&#xD;
          8. Negative pregnancy testing in women with child bearing potential defined as not&#xD;
             post-menopausal for 12 months or no previous surgical sterilization.&#xD;
&#xD;
          9. Patients who cannot take Megace because of past history or elevated risk of DVT,&#xD;
             adrenal insufficiency, impotence, hyperglycemia, CHF, menorrhagia, etc.&#xD;
&#xD;
         10. Patients who have persistent anorexia/cachexia after treatment with Megace has failed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have dementia or delirium on entry into study as determined by the&#xD;
             palliative care specialist using DSM-IV-criteria&#xD;
&#xD;
          2. Patients who are currently taking melatonin&#xD;
&#xD;
          3. Inability to take oral food during the study period&#xD;
&#xD;
          4. Unstable secondary cachexia caused by nausea, diarrhea, taste abnormalities,&#xD;
             mucositis, constipation, dysphagia, or clinical depression prior to study inclusion.&#xD;
             These symptoms should be resolved or stable for &gt;/= 2 weeks at the time of inclusion&#xD;
             into study as determined by the Palliative Care Specialist.&#xD;
&#xD;
          5. Inability to sign informed consent or understand study procedures&#xD;
&#xD;
          6. Karnofsky score of &lt; 40&#xD;
&#xD;
          7. Patients &lt; 18 years of age&#xD;
&#xD;
          8. Patients with &lt;/= 5% involuntary weight loss within the last 6 months and anorexia of&#xD;
             &lt; 3 on ESAS&#xD;
&#xD;
          9. Patients who are on complementary therapies containing melatonin or on medications for&#xD;
             &lt; 2 weeks and not on stable dose&#xD;
&#xD;
         10. Patients who have a cortisol level of &lt;/= 4.3 mg/dL at baseline will be excluded,&#xD;
             unless they are on replacement corticosteroids.&#xD;
&#xD;
         11. Patients with a TSH of &lt;/= 0.50 or &gt;/= 10 mcL/mL at baseline will be excluded&#xD;
&#xD;
         12. Pregnant females or females who are lactating/nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rony Dev, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Joan Karnell Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center</description>
  </link>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>August 6, 2007</study_first_submitted>
  <study_first_submitted_qc>August 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <results_first_submitted>June 6, 2012</results_first_submitted>
  <results_first_submitted_qc>August 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 14, 2012</results_first_posted>
  <last_update_submitted>December 7, 2012</last_update_submitted>
  <last_update_submitted_qc>December 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastrointestinal Cancer</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Cachexia</keyword>
  <keyword>Melatonin</keyword>
  <keyword>Placebo</keyword>
  <keyword>Anorexia</keyword>
  <keyword>Weight Loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 07/21/2006 -04/08/2011. All participants recruited at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 125 participants, there were 52 participants excluded (43 did not meet inclusion criteria; and 9 declined to participate).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Melatonin</title>
          <description>20 mg of Melatonin before going to sleep at night for a period of 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>20 mg of placebo before going to sleep at night for a period of 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>did not receive allocated placebo</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Melatonin</title>
          <description>20 mg of Melatonin before going to sleep at night for a period of 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>20 mg of placebo before going to sleep at night for a period of 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="73"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Age range</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="36" upper_limit="76"/>
                    <measurement group_id="B2" value="62" lower_limit="32" upper_limit="86"/>
                    <measurement group_id="B3" value="59" lower_limit="32" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Appetite as Measured by ESAS</title>
        <description>Difference in ESAS (Edmonton Symptom Assessment Scale) assessment scores of appetite (symptom) from baseline evaluation [± 3 days] to 4 week evaluation [± 3 days], where the severity at the time of assessment is rated from 0 to 10 on a numerical scale; with 0 meaning that the symptom is absent and 10 that it is the worst possible severity.</description>
        <time_frame>Baseline and at 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>20 mg of Melatonin before going to sleep at night for a period of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>20 mg of placebo before going to sleep at night for a period of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Appetite as Measured by ESAS</title>
          <description>Difference in ESAS (Edmonton Symptom Assessment Scale) assessment scores of appetite (symptom) from baseline evaluation [± 3 days] to 4 week evaluation [± 3 days], where the severity at the time of assessment is rated from 0 to 10 on a numerical scale; with 0 meaning that the symptom is absent and 10 that it is the worst possible severity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="2.6" lower_limit="6" upper_limit="8"/>
                    <measurement group_id="O2" value="-1.19" spread="2.3" lower_limit="4" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years and 2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Melatonin</title>
          <description>20 mg of Melatonin before going to sleep at night for a period of 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>20 mg of placebo before going to sleep at night for a period of 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline Phosphatase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <description>Aspartate transaminase (AST), serum glutamic oxaloacetic transaminase (SGOT)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Abdomen</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Constitutional Symptom (other)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Syncope (Fainting)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Egidio Del Fabbro</name_or_title>
      <organization>University of Texas MD Anderson Cancer Center</organization>
      <phone>713-563-4157</phone>
      <email>ammarin@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

